Five minutes of junk food advertising ‘leads children to eat 130 extra calories'
Five minutes of junk food advertising results in children consuming 130 extra calories per day, researchers say.
A study found that advertising and marketing across platforms such as social media, TV and podcasts all had a similar effect.
The research, which has not yet been published in a peer-reviewed journal, was presented at the European Congress on Obesity in Malaga.
The study found that seven to 15-year-olds exposed to five minutes of adverts for foods high in saturated fat, sugar, and/or salt (HFSS) consumed on average 130 extra calories per day – the equivalent of a small chocolate bar.
Lead author, Professor Emma Boyland from the University of Liverpool, said: 'Even short exposure to marketing of foods high in fat, salt and sugar can drive excess calorie consumption and potentially weight gain, particularly in young people who are more susceptible to advertising and whose eating patterns influence their lifelong health.'
The research included 240 children aged seven to 15.
Analysis showed that following exposure to HFSS food ads, children consumed more snacks (an extra 58.4 calories), more lunch (an extra 72.5 calories), and more food overall (snack and lunch combined) than after exposure to non-food advertising.
Those children with a higher body mass index also showed a 'greater responsivity' to the food adverts, experts found.
The Government is introducing a ban on the targeting of junk food adverts at children from October this year.
It estimates this will prevent thousands of cases of childhood obesity.
The restrictions affect advertising for less healthy food or drink on television between 5.30am and 9pm, alongside paid-for advertising online at any time.
Other types of advertising, such as billboards and other outdoor advertising, are not be affected by the change.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Scientists unveil breakthrough drug that could halt and reverse deadly liver fibrosis
Liver fibrosis often develops without symptoms and has no approved cure. But researchers at the University of Sunderland have discovered a new enzyme-blocking treatment that could finally help stop or reverse the disease. Dr Maria Teresa Borrello and her team have found that blocking the enzyme HDAC6 with newly developed drugs could reduce liver scarring in people with fibrosis. HDAC6 plays a role in regulating inflammation and cellular stress, and the research suggests it also helps activate hepatic stellate cells, which are responsible for producing collagen, a major driver of scar tissue formation. Dr Borrello, who is a lecturer in Pharmaceutical and Medicinal Chemistry at the University, said her team has developed two new drugs specifically designed to block HDAC6 activity. 'So far, we've seen encouraging laboratory results showing that HDAC6 inhibitors – or blockers – reduce inflammation and cellular stress responses – both of which are key contributors to fibrosis, she said in a release. 'These findings support the idea that HDAC6 is a promising drug target for treating liver fibrosis. We are also starting to understand more about how these compounds work at the molecular level, which is essential for designing better, safer treatments.' The researchers hope their findings will form the basis of new treatments that can significantly improve the lives of people with this condition and potentially other inflammation-related diseases, including skin disorders. 'This research is a step forward in finding a treatment for liver fibrosis. Our HDAC6 inhibitors provide a more targeted approach and by focusing on a key cause of fibrosis, we may be able to stop the disease before it reaches irreversible stages,' Dr Borello said. 'By stopping or reversing the scarring process, we could reduce the need for liver transplants and improve long-term health outcomes.' Researchers believe that targeting the root cause of fibrosis could mark a turning point in the treatment of liver disease. As efforts to tackle chronic conditions evolve, such precision therapies could change how currently untreatable diseases are managed. The UK's leading liver health charity, the British Liver Trust, has welcomed the research findings. "Liver disease often develops without symptoms, and most people only learn they have liver damage when it's too late for effective treatment - usually limited to a liver transplant or lifestyle changes,' Pamela Healy OBE, Chief Executive at the Trust, said. 'While this new research is still in its early stages, it shows promise for developing treatments that could improve, and ultimately save, the lives of thousands affected by liver disease." Liver disease is responsible for approximately four percent of premature deaths globally, with liver fibrosis being one of its most serious and often undetected forms. In the UK alone, an estimated 2 million people are affected. The condition develops when long-term damage to the liver, commonly caused by alcohol use, obesity, or chronic infections, triggers the formation of scar tissue. As the scarring worsens over time, it can lead to life-threatening complications such as liver failure or cancer. Because symptoms often appear only in the advanced stages, many people are unaware they have the disease, and currently, there are no approved treatments to halt or reverse the scarring study has been published in The Febs Journal.
Associated Press
7 hours ago
- Associated Press
Sire Search Identifies Top 5 Platforms to Boost Biotech Career Growth
Hey, biotech folks! Whether you're a lab whiz itching to land your next role in drug discovery or a hiring manager hunting for the perfect candidate to boost your startup, the life sciences world is buzzing with potential. But, real talk—finding the right job or talent in this fast-moving industry can feel like trying to spot a single cell under a microscope. Overwhelming, right? That's were specialized recruitment websites swoop in like career superheroes. I've rounded up the five best platforms to help you navigate the biotech job maze, and guess what? SIRE Searchis leading the charge with its sharp, tailored approach. Let's dive in and see why these sites are your new allies for crushing it in biotech! 1. – Your Career's Guide A recruitment platform that feels like it knows you better than your lab partner. That's SIRE Searchin a nutshell. Based in Haarlem, Netherlands—a charming spot, by the way—SIRE has been shaking up the life sciences scene since 2012. Whether you're into pharmaceuticals, medical devices, or even fast-moving consumer goods (yep, they've got that covered), SIRE's the place to find your next career win. Their reverse recruitment approach is like a secret weapon. Instead of tossing a pile of job listings your way, they do the heavy lifting first. Using data and market insights, their team—packed with recruiters who actually get biotech—handpicks roles that match your skills and goals. One Trustpilot reviewer raved, 'SIRE landed me a job that's spot-on for my expertise. They were quick and genuinely cared!' With a 4-star rating, they're clearly hitting the mark. 2. – The U.S. Biotech Hub Let's zip over to the States for BioSpace, a heavyweight for biotech and pharma jobs. With over 4,000 active listings, this sites like a treasure chest for anyone looking to dive into or climb higher in the U.S. biotech scene. From lab techs to execs, BioSpace has roles for every step of your journey. What's the deal with BioSpace? It's more than a job board—it's a whole community. You can narrow down searches by niche (like gene therapy or clinical trials) or location, so you're not stuck scrolling through irrelevant posts. They also dish out extras like industry updates, career tips, and their 'Best Places to Work' report, which is like a VIP list for biotech companies. The downside? It's mostly U.S.-focused, so it doesn't have SIRE's global reach. But for North American job seekers, BioSpace is a goldmine. 3. – Your Global Career Connector Dreaming of a biotech career that takes you worldwide? Meet Preclinical. With offices in places like the UK, Singapore, and the U.S., this platform hooks up candidates with roles in everything from drug development to regulatory affairs. It's like having a friend who knows the hottest jobs on every continent. Proclinical's strength is precision. Their recruiters dig into what employers need—skills, culture, the whole package—and match that with a huge candidate network. It's like they're playing career matchmaker, and they're good at it. They don't have SIRE's data-driven reverse recruitment trick, but their global scope is a big win for anyone wanting to think beyond borders. Plus, their blog's full of practical tips, like how to tweak your CV or nail an interview, which is super handy. 4. – The Science Lover's Hangout Next up is New Scientist Jobs, the friendly, all-purpose spot for science buffs. It covers a range of fields, but its biotech section is packed with roles in areas like vaccine research or molecular biology. Whether you're in Europe, the U.S., or elsewhere, this platform's global vibe makes it a welcoming place to explore. Why's it worth your time? It's easy to navigate, with filters to zero in on jobs by expertise or location. Their blog's a gem, too, with career advice and industry scoops that keep you in the loop. It's not as biotech-focused as SIRE, so you might need to sift a bit to find the right role. But if you're curious and love poking around, New Scientist Jobs is a solid bet. 5. – The Job-Finding Shortcut Last up is BioPharmGuy, the quirky underdog we're rooting for. Instead of hosting job listings, it points you straight to biotech company career pages, helping you dodge crowded job boards and find hidden opportunities. It's like a map of buried treasure. You can search by region or niche—like cell therapy or diagnostics—which makes it easy to target your sweet spot. The catch? It's more of a DIY experience, so you won't get the hands-on support you'd find with SIRE's recruiters. But for those who enjoy a bit of career sleuthing, BioPharmGuy is a clever tool to stand out. Why SIRE Search Takes the Crown? Let's give a shoutout to SIRE Searchfor stealing the show. Their reverse recruitment strategy is like having a career coach who's always one step ahead. By tapping into data and market trends, they find roles that fit you like a perfectly calibrated pipette. Their recruiters are biotech enthusiasts who speak your language and genuinely care about your next step. SIRE's focus on Europe—where biotech is thriving—gives them the edge, with connections to everyone from tiny startups to massive corporations. One candidate on Trustpilot said, 'SIRE made my job search feel effortless. They found me a role that's exactly where I want to be.' Employers love them, too, thanks to their knack for delivering candidates who nail both the skills and the vibe. Whether you're after a temp role or a corner office, SIRE's your partner in crime. 5 Tips to Nail Your Biotech Job Hunt Ready to hit these websites and land your dream role? Here's how to make it happen: Let's Wrap It Up The biotech world is full of possibilities, and these websites are your key to unlocking them. SIRE Searchleads the pack with its smart, personalized approach and deep love for life sciences. BioSpace, Preclinical, New Scientist Jobs, and BioPharmGuy are also stellar, each bringing their spark to the table. So, spruce up that resume, dive into these platforms, and get ready to make waves in biotech. Your next big opportunity is out there—grab it! Media Contact Company Name: Sire Search Email: Send Email Address:Staten Bolwerk City: 12011 MK Haarlem Country: Netherlands Website: Press Release Distributed by To view the original version on ABNewswire visit: Sire Search Identifies Top 5 Platforms to Boost Biotech Career Growth
Medscape
13 hours ago
- Medscape
Novo's Ozempic Linked to Rare Cases Of Serious Eye Disorder, EU Regulator Says
(Reuters) -Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European Medicines Agency's safety committee said on Friday. In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic optic neuropathy (NAION). But this is the first time a regulator has confirmed the side effect. The condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Ozempic as well as in Novo's other diabetes drug Rybelsus, for at least one year, the regulator said. NAION is the second-most common cause of blindness due to optic nerve damage, after glaucoma. "This has been reported as a potential risk for some time, so I think the clinical community is relatively aware of it. I don't see this as making any major difference to prescribing patterns," said Barclays analyst Emily Field. U.S.-listed shares of the Danish drugmaker were up nearly 2.5% in early trading. The EMA, which started its review in December, has asked Novo to add NAION as a side effect of very rare frequency in the product information accompanying drugs that contain semaglutide. Novo said it would work with the EMA to update the labels, adding clinical trials and after-market studies did not suggest a reasonable possibility that the drugs caused the condition. The "benefit-risk profile of semaglutide remains favorable," the company said in a statement. Novo has recently faced investor concerns that it is losing its first-mover advantage in the highly competitive obesity treatment market, leading the company to oust CEO Lars Fruergaard Jorgensen in May. Wegovy and Eli Lilly's Zepbound currently dominate the weight-loss drug market, potentially worth about $150 billion by the next decade. The EMA said several large studies in type-2 diabetes patients have suggested that use of Novo's drugs could raise the risk of developing NAION by twofold. A study of nearly 350,000 diabetes patients published in March showed that the risk of developing NAION more than doubled after two years of treatment with Ozempic, compared to patients taking medicines from other classes. The U.S. Department of Health and Human Services did not immediately respond to a Reuters request for comment on whether the Food and Drug Administration was conducting a probe into the side effect. (Reporting by Manas Mishra and Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
